Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated December 12, 2011, reports on the presentation of Phase III clinical trial data at the 53rd Annual Meeting of the American Society of Hematology (ASH). The filing focuses on the efficacy of Tasigna (nilotinib) compared to Glivec (imatinib) in treating Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). The document does not contain financial results for a specific reporting period but references 2010 group net sales of USD 50.6 billion in the "About Novartis" section.
Key Clinical Metrics and Study Results
The filing details results from two major studies, ENESTcmr and ENESTnd, comparing Tasigna to Glivec:
- ENESTcmr (Switch Study): In patients with residual disease after at least two years on Glivec, 23% switched to Tasigna achieved undetectable Bcr-Abl levels within 12 months, compared to 11% who continued on Glivec (p=0.0202). A more stringent endpoint showed 13% on Tasigna versus 6% on Glivec achieved confirmed undetectable Complete Molecular Response (CMR), though this difference was not statistically significant (p=0.108).
- ENESTnd (Newly Diagnosed): After 36 months, 32% of newly diagnosed patients on Tasigna (300 mg twice daily) reached the deepest levels of molecular response versus 15% on Glivec. Tasigna also demonstrated significantly fewer patients progressing to advanced stages of CML and significantly lower CML-related deaths compared to Glivec (p=0.0356).
- Safety and Discontinuation: In ENESTcmr, discontinuation due to adverse events was 8.9% for Tasigna versus 1% for Glivec. In ENESTnd, discontinuation rates were lowest for Tasigna 300 mg (10%) compared to Tasigna 400 mg (14%) and Glivec (11%).
Material Changes and Comparative Analysis
The primary material change highlighted is the superior efficacy of Tasigna over Glivec in achieving deep molecular responses and preventing disease progression. Specifically, the data indicates that switching to Tasigna can double the rate of undetectable disease levels in patients with residual disease. Furthermore, in newly diagnosed patients, Tasigna treatment resulted in significantly fewer CML-related deaths and disease progressions to accelerated phase or blast crisis over a three-year period compared to Glivec.
Outlook, Risks, and Contingencies
Management commentary suggests these findings support the use of Tasigna for adult patients with chronic-phase Ph+ CML and may influence future criteria for therapy discontinuation. The filing includes a standard disclaimer regarding forward-looking statements, noting risks such as regulatory delays, unexpected clinical trial results, patent challenges, and pricing pressures. Safety warnings for Tasigna include risks of QTc prolongation, sudden death in patients with cardiac risk factors, and pancreatitis. Glivec carries risks of severe edema, fluid retention, and liver failure.
Investor Verification Checklist
- Verify the statistical significance of the Complete Molecular Response (CMR) rates between Tasigna and Glivec in the ENESTcmr study (p=0.108 for the stringent endpoint).
- Confirm the long-term safety profile of Tasigna regarding cardiac events and pancreatitis as noted in the safety information.
- Assess the potential impact of these clinical results on future revenue projections for Tasigna versus Glivec, noting the disclaimer that no guarantees are made regarding future revenue levels.
- Review the full prescribing information for both drugs to understand the specific contraindications and monitoring requirements for patients.
- Check for any subsequent regulatory approvals or label changes for Tasigna based on the ENESTnd and ENESTcmr data presented.